Overall, treatment with GLP-1 receptor agonists in patients with T2D reduced the risk of three-point MACE by 14% (HR: 0.88; 95% CI: 0.82–0.94; p = 0.0001), and the composite kidney outcome consisting of development of macroalbuminuria, worsening of kidney function (based on eGFR change), kidney replacement therapy, or death due to kidney disease by 21% (HR: 0.79; 95% CI: 0.73–0.87) with treatment effect at least as large in patients with eGFR < 60 mL/min/1.73 m2 [83]. This evidence concerns the gene GLP1R and kidney disorder.